PMID- 31956150
OWN - NLM
STAT- MEDLINE
DCOM- 20200219
LR  - 20200219
IS  - 1349-3299 (Electronic)
IS  - 1349-2365 (Linking)
VI  - 61
IP  - 1
DP  - 2020 Jan 31
TI  - Heart is the Target Organ of Endogenous Cardiac Natriuretic Peptides.
PG  - 77-82
LID - 10.1536/ihj.19-379 [doi]
AB  - This study aimed to evaluate whether the heart is the target organ of endogenous 
      atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in patients 
      with heart failure (HF) with reduced ejection fraction (HFrEF).We measured the 
      plasma levels of cyclic guanosine monophosphate (cGMP), which is a second 
      messenger of ANP and BNP, in the aortic root (AO) and coronary sinus (CS) in 237 
      patients with HFrEF. Plasma levels of cGMP were significantly higher in the CS 
      than those in the AO in 237 patients with HFrEF (10.0 +/- 4.5 versus 10.5 +/- 4.3 
      pmoL/mL, P < 0.0001) and were significantly higher in the CS than those in the AO 
      (8.0 +/- 3.6 versus 8.9 +/- 3.8 pmoL/mL, P < 0.0001) in mild HF patients (New York 
      Heart Association (NYHA) II, n = 114), but there was no difference in plasma cGMP 
      between the AO and the CS (11.9 +/- 4.4 versus 11.9 +/- 4.3 pmoL/mL, NS) in severe HF 
      patients (NYHA III-IV, n = 123). In mild HF patients, log (ANP + BNP) in the AO 
      was an independent predictor of (CS-AO) cGMP among hemodynamics and nitrate 
      therapy. There was a significant correlation between log [(CS-AO) ANP + (CS-AO) 
      BNP] and (CS-AO) cGMP (r = 0.455, P < 0.0001) in mild HF patients.These findings 
      indicate that cGMP is produced from the failing heart and that the heart is the 
      target organ of endogenous ANP and BNP in patients with HFrEF. In severe HF 
      patients, cGMP production may be attenuated because of the downregulation of 
      biological receptors and/or increased cGMP degradation in the failing heart.
FAU - Tsutamoto, Takayoshi
AU  - Tsutamoto T
AD  - Department of Cardiovascular Medicine, Shiga University of Medical Science.
FAU - Sakai, Hiroshi
AU  - Sakai H
AD  - Department of Cardiovascular Medicine, Shiga University of Medical Science.
FAU - Yamamoto, Takashi
AU  - Yamamoto T
AD  - Department of Cardiovascular Medicine, Shiga University of Medical Science.
FAU - Nakagawa, Yoshihisa
AU  - Nakagawa Y
AD  - Department of Cardiovascular Medicine, Shiga University of Medical Science.
LA  - eng
PT  - Journal Article
DEP - 20200117
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - H2D2X058MU (Cyclic GMP)
SB  - IM
MH  - Aged
MH  - Atrial Natriuretic Factor/*metabolism
MH  - Cardiac Catheterization
MH  - Cyclic GMP/blood
MH  - Female
MH  - Heart Failure/blood/metabolism/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*metabolism
MH  - Stroke Volume
OTO - NOTNLM
OT  - Atrial natriuretic peptide
OT  - Brain natriuretic peptide
OT  - Cyclic guanosine monophosphate
OT  - Heart failure
OT  - Heart failure with reduced ejection fraction
EDAT- 2020/01/21 06:00
MHDA- 2020/02/20 06:00
CRDT- 2020/01/21 06:00
PHST- 2020/01/21 06:00 [pubmed]
PHST- 2020/02/20 06:00 [medline]
PHST- 2020/01/21 06:00 [entrez]
AID - 10.1536/ihj.19-379 [doi]
PST - ppublish
SO  - Int Heart J. 2020 Jan 31;61(1):77-82. doi: 10.1536/ihj.19-379. Epub 2020 Jan 17.